RT Journal Article
SR Electronic
T1 Evaluation of commercially available high-throughput SARS-CoV-2 serological assays for serosurveillance and related applications
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.09.04.21262414
DO 10.1101/2021.09.04.21262414
A1 Stone, Mars
A1 Grebe, Eduard
A1 Sulaeman, Hasan
A1 Di Germanio, Clara
A1 Dave, Honey
A1 Kelly, Kathleen
A1 Biggerstaff, Brad
A1 Crews, Bridgit O.
A1 Tran, Nam
A1 Jerome, Keith R.
A1 Denny, Thomas N.
A1 Hogema, Boris
A1 Destree, Mark
A1 Jones, Jefferson M.
A1 Thornburg, Natalie
A1 Simmons, Graham
A1 Krajden, Mel
A1 Kleinman, Steve
A1 Dumont, Larry J.
A1 Busch, Michael P.
YR 2021
UL http://medrxiv.org/content/early/2021/09/15/2021.09.04.21262414.abstract
AB SARS-CoV-2 serosurveys can estimate cumulative incidence for monitoring epidemics but require characterization of employed serological assays performance to inform testing algorithm development and interpretation of results. We conducted a multi-laboratory evaluation of 21 commercial high-throughput SARS-CoV-2 serological assays using blinded panels of 1,000 highly-characterized blood-donor specimens. Assays demonstrated a range of sensitivities (96%-63%), specificities (99%-96%) and precision (IIC 0.55-0.99). Durability of antibody detection in longitudinal samples was dependent on assay format and immunoglobulin target, with anti-spike, direct, or total Ig assays demonstrating more stable, or increasing reactivity over time than anti-nucleocapsid, indirect, or IgG assays. Assays with high sensitivity, specificity and durable antibody detection are ideal for serosurveillance. Less sensitive assays demonstrating waning reactivity are appropriate for other applications, including characterizing antibody responses after infection and vaccination, and detection of anamnestic boosting by reinfections and vaccine breakthrough infections. Assay performance must be evaluated in the context of the intended use.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by research contracts from the Centers for Disease Control and Prevention (CDC Contract 75D30120C08170).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All blood donors consented to use of de-identified, residual specimens for further research purposes. UCSF IRB provided explicit approval for VRI self-certification that use of the de-identified CCP donations in this study does not meet the criteria for human subjects research. CDC investigators reviewed and relied on this determination as consistent with applicable federal law and CDC policy (45 C.F.R. part 46, 21 C.F.R. part 56; 42 U.S.C. Sect. 241(d); 5 U.S.C. Sect. 552a; 44 U.S.C. Sect. 3501).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe analytic data set is available upon request.